Indeed, a salient finding is that MDSCs based on flow cytometrical analysis and immunosuppressive CD163+ (i.e. M2-polarized) TAMs based on immunohistochemistry are not affected by eMSC treatment and remain abundant in the TME, even upon tumor growth reduction. Here, CD163 is linked to neoplasm.